[{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Not Applicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Not Applicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal"},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv Biosciences"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"BioLineRx","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ BlackRock","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ BlackRock"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Ayrmid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioLineRx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioLineRx \/ Ayrmid","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Ayrmid"}]

Find Clinical Drug Pipeline Developments & Deals for Filgrastim

Filgrastim
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pp

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Filgrastim

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 2 USDMF, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

FINISHED DOSAGE FORMULATIONS

125 FDF Dossiers, 14 FDA Orange Book, 71 Europe, 11 Canada, 10 Australia, 12 South Africa, 7 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 2 SPI Pharma, 1 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 2 Actylis, 1 BASF, 3 Gangwal Chemicals, 1 Nanjing Bold Chemical, 11 Roquette, 6 Seppic, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

11 Film Formers & Plasticizers, 10 Solubilizers, 7 Parenteral, 4 Taste Masking, 4 Coating Systems & Additives, 4 Fillers, Diluents & Binders, 3 Emulsifying Agents, 3 Topical, 2 Chewable & Orodispersible Aids, 2 Thickeners and Stabilizers, 2 Direct Compression, 2 Co-Processed Excipients, 2 Surfactant & Foaming Agents, 1 API Stability Enhancers, 1 Soft Gelatin, 1 Rheology Modifiers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 43 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

43 Finished Drug Prices, 16 Annual Reports

MARKET PLACE

6 APIs, 16 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 JP, 2 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

Antibody Engineering

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Natural killer cells,Filgrastim,Fludarabine Phosphate

Therapeutic Area : Oncology

Study Phase : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Kiadis Pharma announces new data on ex-vivo FC21

Details : The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).

Brand Name : Undisclosed

Molecule Type : Cell and Gene therapy

Upfront Cash : Not Applicable

March 10, 2020

Lead Product(s) : Natural killer cells,Filgrastim,Fludarabine Phosphate

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

BioLineRx

Israel

Antibody Engineering

Not Confirmed

03

BioLineRx

Israel

Antibody Engineering

Not Confirmed

04

BioLineRx

Israel

Antibody Engineering

Not Confirmed

05

Amneal Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

06

Amneal Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

07

Recardio

U.S.A

Antibody Engineering

Not Confirmed

08

Kashiv Specialty Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

09

Recardio

U.S.A

Antibody Engineering

Not Confirmed

10

Recardio

U.S.A

Antibody Engineering

Not Confirmed

1
2